Laboratorio Reig Jofre

Laboratorio Reig Jofre EBIT Margin

The EBIT Margin (Operating Margin) of Laboratorio Reig Jofre (RJF.MC) as of Nov 14, 2026 is 4.42 %. In the previous year, EBIT Margin (Operating Margin) was 3.87 % — a change of 14.37% (higher).

EBIT Margin

4.42 %

YoY

14.37%

Last updated:

EBIT Margin (Operating Margin) of Laboratorio Reig Jofre is 2024 4.42 % . EBIT Margin (Operating Margin) of Laboratorio Reig Jofre was 2023 3.87 % . It decreases by 14.37% higher compared to the previous year.

Laboratorio Reig Jofre's operating (EBIT) margin stands at 4.4%, broadly stable from 4.2% several years earlier.

The Laboratorio Reig Jofre EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2017
5.37 EUR
Jan 1, 2018
4.89 EUR
Jan 1, 2019
3.28 EUR
Jan 1, 2020
4.17 EUR
Jan 1, 2021
3.94 EUR
Jan 1, 2022
3.51 EUR
Jan 1, 2023
3.87 EUR
Jan 1, 2024
4.42 EUR
The Laboratorio Reig Jofre EBIT Margin history
YEAREBIT MarginYoY
4.42 %+14.37%
3.87 %+10.34%
3.51 %-10.95%
3.94 %-5.55%
4.17 %+27.08%
3.28 %-32.95%
4.89 %-8.93%
5.37 %-11.52%
6.07 %-18.94%
7.49 %-10.87%
8.40 %+6,455.21%
0.13 %+101.25%
0.06 %+1,804.46%
0.00-101.83%
-0.18 %-7.29%
-0.20 %+80.76%
-0.11 %-231.89%
0.08 %-3.32%
0.09 %+68.64%
0.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorio Reig Jofre Stock analysis

What does Laboratorio Reig Jofre do? Laboratorio Reig Jofre SA is a leading company in the pharmaceutical industry, specializing in the development, manufacturing, and marketing of drugs. The company was founded in 1929 by the Reig Jofre brothers in Barcelona, Spain. It has since become an international company with a wide portfolio of products and a high level of innovation and quality. The business model of Laboratorio Reig Jofre SA is based on implementing research and innovation in the field of pharmacy. The company has its own R&D department, which collaborates closely with major scientific organizations and universities in Spain to understand and apply the latest developments and innovations in the industry. Laboratorio Reig Jofre SA has three main divisions - human pharmaceuticals, veterinary medicine, and chemical products used in various industries such as cosmetics and food. The human pharmaceutical division includes a variety of products, including prescription drugs, over-the-counter products, and generics, with a focus on therapy areas such as oncology, antibiotics, gynecology, and central nervous system disorders. The veterinary medicine division provides a wide range of vaccines and medications for animal health. The third division of chemical products includes various products such as emulsifiers, preservatives, and natural dyes that can be used in different industries. Some of the most well-known products of Laboratorio Reig Jofre SA include the antibiotic Nitrofurantoin, the analgesic Algiasdin, the hormonal preparation Ovusitol, and the vaccine against Bluetongue in animals. The company has also carried out several successful acquisitions to expand its portfolio and strengthen its international presence. The acquisition of Derivados Quimicos SA (Derma SA) introduced Laboratorio Reig Jofre SA to the skincare sector and strengthened its presence in Latin America. The acquisition of Bioiberica SA introduced the company to the field of bioactive molecules and chondroprotectants. Laboratorio Reig Jofre SA is a company that places quality and innovation at the heart of its activities. The company has a strong corporate culture based on respect, transparency, integrity, and commitment. It has also shown a strong commitment to sustainability and social responsibility, with initiatives such as supporting projects to improve the health of women and children in Africa and implementing environmentally friendly practices in production. Overall, Laboratorio Reig Jofre SA is a leading company in the pharmaceutical industry, capable of offering a wide range of products through research, innovation, and quality. With its diverse portfolio of products and its commitment to sustainability and social responsibility, the company is well-equipped to continue playing a leading role in the industry in the future. Laboratorio Reig Jofre is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorio Reig Jofre stock

EBIT Margin (Operating Margin) of Laboratorio Reig Jofre is 4.42 % in 2024.

EBIT Margin (Operating Margin) of Laboratorio Reig Jofre changed from 3.87 % to 4.42 %, representing a 14.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Laboratorio Reig Jofre since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Laboratorio Reig Jofre with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Laboratorio Reig Jofre

All Key Metrics — Laboratorio Reig Jofre